Dendritic cells in MDS and AML - Cause, effect or solution to the immune pathogenesis of disease?

Leukemia

Volumn 19, Issue 3, 2005, Pages 354-357

  Panoskaltsis, N ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER RISK; DENDRITIC CELL; DISEASE MODEL; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKEMIA REMISSION; LEUKEMOGENESIS; MOLECULAR CLONING; MOLECULAR DYNAMICS; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR IMMUNITY; CELL CLONE; IMMUNOLOGY; NEOPLASM; NOTE; PATHOLOGY;

CLONE CELLS; DENDRITIC CELLS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MYELODYSPLASTIC SYNDROMES; NEOPLASMS;

EID: 15044363362     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403634     Document Type: Article

References (42)

1. Ma L, Delforge M, Van Duppen V, Verhowef G, Emanuel B, Boogaerts M et al. Circulating myeloid and lymphoid precursor dendritic cells are clonally involved in myelodysplastic syndromes. Leukemia 2004; 18: 1451-1456.
2. Mohty M, Jarrossay D, Lafage-Pochitaloff M, Zandotti C, Briere F, de Lamballeri X et al. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood 2001; 98 3750-3756.
3. Robinson SP, English N, Jaju R, Kearney L, Knight SC, Reid CDL. The in-vitro generation of dendritic cells from blast cells in acute leukaemia. Br J Haematol 1998; 103: 763-771.
4. Panoskaltsis N, Belanger TJ, Liesveld JL, Abboud CN. Optimal cytokine stimulation for the enhanced generation of leukemic dendritic cells in short-term culture. Leuk Res 2002; 26: 191-201.
5. Harrison BD, Adams JA, Brigs M, Brereton ML, Liu Yin JA. Stimulation of autologous proliferative and cytotoxic T-cell responses by 'leukemic dendritic cells' derived from blast cells in acute myeloid leukemia. Blood 2001; 97: 2764-2771.
6. Panoskaltsis N, Reid CDL, Knight SC. Immune modulation with dendritic cells. Transfus Med 2004; 14: 81-96.
7. Robinson SP, Patterson S, English N, Davies D, Knight SC, Reid CDL. Human peripheral blood contains two distinct lineages of dendritic cells. Eur J Immunol 1999; 29: 2769-2778.
8. Soumelis V, Scott I, Gheyas F, Bouhour D, Cozon G, Cotte L et al. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood 2001; 98: 906-912.
9. Knight SC, Burke F, Bedford PA. Dendritic cells, antigen distribution and the initiation of primary immune responses to self and non-self antigens. Cancer Biol 2002; 12: 301-308.
10. Hersh EM, Whitecar JP, McCredie KB, Bodey GP, Freireich EJ. Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukemia. N Engl J Med 1971; 285: 1211-1216.
11. Reid CDL. Dendritic cells and immunotherapy for malignant disease. Br J Haematol 2001; 112: 874-887.
12. Costello RT, Mallet F, Gaugler B, Sainty D, Arnoulet C, Gastaut J et al. Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res 2000; 60: 4403-4411.
13. Buggins AGS, Milojkovic D, Arno MJ, Lea NC, Mufti GJ, Thomas NSB et al. Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-κB, c-Myc, and pRb pathways. J Immunol 2002; 167: 6021-6030.
14. Panoskaltsis N, Reid CDL, Knight SC. Quantification and cytokine production of circulating lymphoid and myeloid cells in acute myelogenous leukemia (AML). Leukemia 2003; 17: 716-725.
15. Catovsky D, Lauria F, Matutes E, Foa R, Mantovani V, Tura S et al. ncrease in Tγ lymphocytes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1981; 47: 539-544.
16. Dowding C, Th'ng KH, Goldman JM, Galton DAG. Increased T-lymphocyte numbers in chronic granulocytic leukemia before treatment. Exp Hematol 1984; 12: 811-815.
17. Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002; 100: 2132-2137.
18. Buggins AGS, Hirst WJR, Pagliuca A, Mufti GJ. Variable expression of CD3-zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies. Br J Haematol 1998; 100: 784-792.
19. Trimble LA, Kam LW, Friedman RS, Xu Z, Lieberman J. CD3ζ and CD28 down-modulation on CD8T cells during viral infection. Blood 2000; 96: 1021-1029.
20. Krishnan S, Warke VG, Nambiar MP, Wong HK, Tsokos GC, Farber DL. Generation and biochemical analysis of human effector CD4 T cells: alterations in tyrosine phosphorylation and loss of CD3ζ expression. Blood 2001; 97: 3851-3859.
21. Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002; 100: 3639-3645.
22. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6 1018-1023.
23. Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest 2003; 111: 639-647.
24. Elisseeva OA, Oka Y, Tsuboi A, Ogata K, Wu F, Kim EH et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002; 99: 3272-3279.
25. Stavely-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 1998; 95: 1178-1183.
26. Takasugi M, Ramseyer A, Takasugi J. Decline of natural nonselective cell-mediated cytotoxicity in patients with tumor progression. Cancer Res 1977; 37: 413-418.
27. Mintz PJ, Kim J, Do K-A, Wang X, Zinner RG, Cristofanilli M et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 2003; 21: 57-63.
28. Valmori D, Dutoit V, Lienard D, Lejeune F, Speiser D, Rimoldi D et al. Tetramer-guided analysis of TCR β-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients. J Immunol 2000; 165: 533-538.
29. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-1759.
30. Kelly LM, Kutok JL, Williams IR, Boulton CL, Amaral SM, Curley DP et al. PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci USA 2002; 99: 8283-8288.
31. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998; 92: 3362-3367.
32. Liu Y, Hernandez AM, Shibata D, Cortopassi GA. BCL2 translocation frequency rises with age in humans. Proc Natl Acad Sci USA 1994; 91: 8910-8914.
33. Basecke J, Cepek L, Mannhalter C, Krauter J, Hildenhagen S, Brittinger G et al. Transcription of AML1/ETO in bone marrow and cord blood of individuals without acute myelogenous leukemia. Blood 2002; 100: 2267-2268.
34. Wiemels JL, Ford AM, Van Wering ER, Postma A, Greaves M. Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero. Blood 1999; 94: 1057-1062.
35. Wiemels JL, Xiao Z, Buffler PA, Maia AT, Ma X, Dicks BM et al. In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood 2002; 99: 3801-3805.
36. Ford A, Bennett CA, Price CM, Bruin MCA, Van Bering ER, Greaves M. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc Natl Acad Sci USA 1998; 95: 4584-4588.
37. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532-1542.
38. Mohty M, Olive D, Gaugler B. Leukemic dendritic cells: potential for therapy and insights towards immune escape by leukemic blasts. Leukemia 2002; 16: 2197-2204.
39. Allan JM, Wild CP, Rollinson S, Willett EV, Moorman AV, Dovey GJ et al. Polymorphism in glutathione S-transferase P1 is associated wih susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA 2001; 98: 11592-11597.
40. Strick R, Strissel PL, Borgers S, Smith SL, Rowley JD. Dietary bioflavonoids induce cleavage in the MII gene and may contribute to infant leukemia. Proc Natl Acad Sci USA 2000; 97: 4790-4795.
41. Giles FJ, Keating A, Goldstone AH, Avivi I, Willman Ch, Kantarjian HM. Acute myeloid leukemia. In: Broudy VC, Abkowitz JL, Vose JM (eds). Hematology 2002. Washington, DC: The American Society of Hematology, 2002, pp 73-110.
42. Qian Z, Fernald AA, Godley LA, Larson RA, Le Beau MM. Expression profiling of CD34+ hematopoietic stem progenitor ells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci USA 2002; 99: 14925-14930.